ATE377606T1 - Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren - Google Patents

Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren

Info

Publication number
ATE377606T1
ATE377606T1 AT98930536T AT98930536T ATE377606T1 AT E377606 T1 ATE377606 T1 AT E377606T1 AT 98930536 T AT98930536 T AT 98930536T AT 98930536 T AT98930536 T AT 98930536T AT E377606 T1 ATE377606 T1 AT E377606T1
Authority
AT
Austria
Prior art keywords
receptors
protein coupled
coupled receptors
cyclic antagonists
protein
Prior art date
Application number
AT98930536T
Other languages
German (de)
English (en)
Inventor
David Fairlie
Stephen Taylor
Angela Finch
Allan Wong
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Application granted granted Critical
Publication of ATE377606T1 publication Critical patent/ATE377606T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
AT98930536T 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren ATE377606T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist

Publications (1)

Publication Number Publication Date
ATE377606T1 true ATE377606T1 (de) 2007-11-15

Family

ID=3801840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930536T ATE377606T1 (de) 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren

Country Status (11)

Country Link
US (5) USRE41287E1 (https=)
EP (1) EP1017713B1 (https=)
JP (1) JP4686696B2 (https=)
AT (1) ATE377606T1 (https=)
AU (2) AUPO755097A0 (https=)
CY (1) CY1107133T1 (https=)
DE (1) DE69838678T2 (https=)
DK (1) DK1017713T3 (https=)
ES (1) ES2294816T3 (https=)
PT (1) PT1017713E (https=)
WO (1) WO1999000406A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
CA2418652C (en) 2000-08-10 2010-03-23 Mitsubishi Pharma Corporation Novel 3-substituted urea derivatives and medicinal use thereof
WO2002022556A1 (en) 2000-09-14 2002-03-21 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof ugs
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
US8524862B2 (en) 2002-03-19 2013-09-03 Cincinnati Children's Hospital Medical Center Muteins of C5a anaphylatoxin and methods of inhibiting C5a
CA2480082A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
JP4818726B2 (ja) * 2002-10-16 2011-11-16 プロミクス・プロプライエタリー・リミテッド 炎症性腸疾患の治療
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
JP2008516194A (ja) * 2004-10-04 2008-05-15 アルケミア リミティッド 選択的阻害剤
RU2007131267A (ru) * 2005-01-17 2009-02-27 Йерини Аг (De) АНТАГОНИСТЫ РЕЦЕПТОРА С5a
EP1861114B1 (en) * 2005-03-11 2011-02-02 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100000605A1 (en) * 2008-07-02 2010-01-07 Saint-Gobain Performance Plastics Chaineux Framed device, seal, and method for manufacturing same
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2011091366A2 (en) * 2010-01-22 2011-07-28 University Of Louisville Research Foundation, Inc. Methods of treating or preventing periodontitis and diseases associated with periodontitis
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
WO2012006149A2 (en) * 2010-06-29 2012-01-12 Board Of Regents Of The University Of Nebraska Analogs of c5a and methods of using same
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10092620B2 (en) * 2013-04-02 2018-10-09 The Scripps Research Institute Uses of cyclic peptides for treating and preventing atherosclerosis
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US20190270778A1 (en) 2016-07-29 2019-09-05 Pfizer Inc. Cyclic Peptides As C5a Receptor Antagonists
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
TWI786132B (zh) 2017-06-23 2022-12-11 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
PH12022552556A1 (en) 2020-03-27 2024-04-22 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
JP2023525581A (ja) 2020-05-15 2023-06-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
WO1995016033A1 (en) 1993-12-06 1995-06-15 Ciba-Geigy Ag C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Also Published As

Publication number Publication date
DE69838678D1 (de) 2007-12-20
US20130005644A1 (en) 2013-01-03
US20060160726A1 (en) 2006-07-20
EP1017713A1 (en) 2000-07-12
PT1017713E (pt) 2007-12-18
WO1999000406A1 (en) 1999-01-07
US20090203760A1 (en) 2009-08-13
AU744991B2 (en) 2002-03-07
AUPO755097A0 (en) 1997-07-17
AU8092698A (en) 1999-01-19
EP1017713A4 (en) 2002-07-24
US6821950B1 (en) 2004-11-23
DE69838678T2 (de) 2008-10-30
EP1017713B1 (en) 2007-11-07
CY1107133T1 (el) 2012-10-24
HK1029595A1 (en) 2001-04-06
DK1017713T3 (da) 2008-02-11
JP4686696B2 (ja) 2011-05-25
USRE41287E1 (en) 2010-04-27
ES2294816T3 (es) 2008-04-01
JP2002508767A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
ATE377606T1 (de) Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
IS5543A (is) Nýr G próteintengdur viðtaki
EA200300663A1 (ru) Антагонисты cxcr3
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
DE60329030D1 (de) Melanocortin-rezeptormodulatoren
PT934310E (pt) N-heterociclicos monociclicos substituidos por tioacido uteis como anti-coagulantes
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
YU34898A (sh) Antagonisti ccr-3 receptora
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
EA200400816A1 (ru) Замещенные аналоги хиназолин-4-иламина в качестве модуляторов капсаицина
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
ATE344261T1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
DE60038686D1 (de) Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
CY1107739T1 (el) Ανταγωνιστες υποδοχεων οπιοειδων σε διαδερματικα συστηματα με μπουπρενορφινη
ATE266722T1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
BR0011122A (pt) Antagonistas de receptor il-8
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
ATE273389T1 (de) Rezeptor des y-y5 neuropeptids
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
ATE343634T1 (de) Gaba b-rezeptor-subtypen gaba b-r1c und gaba b-r2 und deren heterodimere

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017713

Country of ref document: EP